In breast cancer, ELOVL2 acts as a tumor suppressor by attenuating tamoxifen resistance (Jeong et al., 2021), whereas in renal cell carcinoma, it promotes tumor progression by inhibiting apoptosis. The gene discussed is ELOVL2; the disease is neoplasm.